The Cancer Survivors Network (CSN) is a peer support community for cancer patients, survivors, caregivers, families, and friends! CSN is a safe place to connect with others who share your interests and experiences.
Please let me know which of these studies you are interested in reading
click here to view this message online
Prostate Cancer
A discussion of the value and benefit of transrectal power Doppler sonography for detecting low-risk prostate cancers, "Beyond the Abstract," by J.-L. Sauvain, and E. Sauvain Secondary circulating prostate cells predict biochemical failure in prostate cancer patients after radical prostatectomy and without evidence of disease - Abstract Racial differences in social support and coping among family caregivers of patients with prostate cancer - Abstract Prostate cancer risk in rre-diabetic men: A matched cohort study - Abstract High dose rate brachytherapy as monotherapy for localised prostate cancer: A hypofractionated two-implant approach in 351 consecutive patients - Abstract Real-time contrast-enhanced transrectal US-guided prostate biopsy: Diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings - Abstract Can delayed time to referral to a tertiary level urologist with an abnormal PSA level affect subsequent Gleason grade in the opportunistically screened population? - Abstract Sentinel lymph node dissection in more than 1200 prostate cancer cases: Rate and prediction of lymph node involvement depending on preoperative tumor characteristics - Abstract Application and clinical benefits of degarelix, a GnRH antagonist, in the treatment of advanced prostate cancer, "Beyond the Abstract," by Neal D. Shore, MD, FACS Statement by NIH Director Francis Collins on U.S. Supreme Court ruling on gene patenting Breaking News: Can someone else patent your genes? No, according to a closely watched ruling from the U.S. Supreme Court Thursday ASCO 2013 - Poster: Results from a phase I study of enzalutamide in combination with docetaxel in men with prostate cancer ASCO 2013 - Poster: A phase II multicenter study of the investigational single agent orteronel (TAK-700) in non-metastatic castration-resistant prostate cancer (nmCRPC [M0]) and rising prostate-specific antigen (PSA) Radiotherapy with rectangular fields is associated with fewer clinical failures than conformal fields in the high-risk prostate cancer subgroup: Results from a randomized trial - Abstract Sperm banking is of key importance in patients with prostate cancer - Abstract Patients undergoing radical prostatectomy have a better survival than the background population - Abstract Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer - Abstract Classifying the reasons men consider to be important in prostate-specific antigen (PSA) testing decisions: Evaluating risks, lay beliefs, and informed decisions - Abstract Plan of the day selection for online image-guided adaptive post-prostatectomy radiotherapy - Abstract Current role of surgery for high risk prostate cancer - Abstract Cost-benefit of incorporating the detection of circulating prostate cells in a screening programme for prostate cancer - Abstract Platinum-based chemotherapy for variant castrate-resistant prostate cancer - Abstract Functional and molecular imaging of localized and recurrent prostate cancer - Abstract PSA screening and deaths from prostate cancer after diagnosis-A population based analysis - Abstract Discussing uncertainty and risk in primary care: Recommendations of a multi-disciplinary panel regarding communication around prostate cancer screening - Abstract Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer - Abstract
